Bringing synthetic biology to transcriptional regulation could catalyse a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field.
Artificial Intelligence is a hot topic of conversation in pretty much every industry all the way from manufacturing to education.
The past decade has seen a resurgence in the field of cell and gene therapy, with three treatments being approved by the European Medicines Agency and the US Food and Drug Administration and a flood of candidate therapies
The research and development agreement will develop synthetic promoters for use in immune system cells including lymphoid, myeloid and microglia cells.
Synpromics announces the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development.